AU2002231784A1 - Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture - Google Patents
Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial cultureInfo
- Publication number
- AU2002231784A1 AU2002231784A1 AU2002231784A AU2002231784A AU2002231784A1 AU 2002231784 A1 AU2002231784 A1 AU 2002231784A1 AU 2002231784 A AU2002231784 A AU 2002231784A AU 2002231784 A AU2002231784 A AU 2002231784A AU 2002231784 A1 AU2002231784 A1 AU 2002231784A1
- Authority
- AU
- Australia
- Prior art keywords
- protein
- dna
- supernatant
- insulin
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
FUSION PROTEIN FOR THE SECRETION OF A PROTEIN OF INTEREST INTO THE SUPERNATANT OF THE BACTERIAL CULTURE
Description 5 The invention relates to fusion proteins comprising a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into the supernatant of a bacterial host and the protein of interest being present in its correct three-dimensional structure. The gene sequence for the fusion 0 protein is part of an expression cassette which allows expression in a bacterial host. The invention relates to a process for the fermentation, expression and work-up of such a fusion protein using the expression cassette, to a plasmid containing the expression cassette, to a bacterial host cell containing the expression cassette integrated into the chromosome and/or as a replicon, for example as a plasmid, to said 5 fusion protein with hirudin or a derivative thereof as the fusion part, to a process for producing insulin or an insulin derivative and to the use of the expression cassette in the processes for preparing a fusion protein from hirudin or derivatives thereof and for producing insulin or an insulin derivative.
0 The development of optimized processes for producing pharmaceuticals on the basis of recombinant proteins represents a task which has to do justice to two points of view, if possible. First, a process ought to be as cost-effective as possible and secondly, the product ought to be of the highest purity.
In this connection, the choice of expression system determines the course of the particular production process, and it is obvious to the skilled worker that the development of novel protein-chemical techniques and the wide variety of biochemical possibilities and new combinations of known techniques always make improvements of existing processes possible.
The properties of a desired protein determine in a decisive way the choice of the host cell system used for the synthesis. Bacteria such as E. coli represent the system with the aid of which it is possible to rapidly produce proteins with crude yields of several
grams in inexpensive media. The system comes in useful especially for proteins which need not be modified and which can be renatured in vitro to their biologically active form. For proteins which are needed in high quantities, such as insulin for example, expression rates leading to intracellular accumulation of the protein in the form of inclusion bodies are aimed at. After cell lysis, the protein is dissolved and then, in further process steps, folded. However, the process of folding is not quantitative. Reasons for this may be irreversible damage during inclusion body formation, corresponding damage during cell lysis and errors during folding. "Wrongly" folded or modified molecules then have to be removed in further separation steps. This has an adverse effect on production costs. In addition, traces of said molecules reappear also in the final product. Since pharmaceuticals are subject to high criteria of purity, an appropriately careful and cost-intensive purification is necessary. Owing to the favorable cost / crude yield ratio, processes allowing export by E. coli of the protein of interest in correctly folded form into the culture medium would be of desirable. However, this has been successful only in exceptional cases up until now.
The international patent application PCT/EP00/08537 describes such an exception. Synthesis and export of lepirudin, the active ingredient of the pharmaceutical Refludan®, by E. coli in gram quantities was successful when using specific signal sequences for exporting. The German patent application No. 100 33 195.2 (unpublished) describes a bifunctional protein composed of hirudin and hirudin derivatives and of factor Xa inhibitor from ticks and derivatives thereof. Said protein can likewise be synthesized and exported by E. coli with high yields. As an addition to this finding, it was then surprisingly found that hirudin is exported with high yields not only as a fusion protein with TAP but also as part of a fusion protein with polypeptides such as proinsulin derivatives, that it is biologically active and that surprisingly a fusion partner such as proinsulin is present in the correct three-dimensional structure. This unexpected result leads to the possibility of more cost-effective production of, for example, insulin by bacterial host/vector systems, since the step of in vitro refolding after intracellular expression, which is associated with losses in yield which are not negligible, can be dispensed with and in this way a simpler protein purification process results. Another advantage is that chaotropic aids which are added to dissolve the
fusion protein in traditional processes for the production of insulin in E. coli are not required. Ecologically, this leads to less environmental pollution by avoiding the corresponding waste.
Leeches of the Hirudo type have developed, for example, various isoforms of the thrombin inhibitor hirudin. Hirudin has been optimized for pharmaceutical requirements by artificial variation of the molecule, for example exchange of the N-terminal amino acid (e.g. EP-A 0 324 712).
The invention includes the use of hirudin and hirudin variants for the formation of fusion proteins, for example with simian proinsulin or derivatives thereof. Particular embodiments of the invention use one of the natural hirudin isoforms (the natural isoforms together are denoted "hirudin"). Natural isoforms are, for example, Val-Val- hirudin or lle-Thr-hirudin. Other embodiments of the invention use a variant of a natural hirudin isoform. A variant is derived from a natural hirudin isoform but contains, for example, additional amino acids and/or amino acid deletions and/or amino acid exchanges compared with the natural isoform. A hirudin variant may contain alternating peptide segments of natural hirudin isoforms and new amino acids. Hirudin variants are known and are described, for example, in DE 3 430 556. Hirudin variants are commercially available in the form of proteins (Calbiochem® Biochemicals, Cat.no.377-853, -950-960).
Insulin is a polypeptide of 51 amino acids which are distributed between two amino acid chains: the A chain with 21 amino acids and the B chain with 30 amino acids. The chains are connected to one another by 2 disulfide bridges. Insulin compositions have been used for many years for the therapy of diabetes. This includes the use not only of naturally occurring insulins but also of insulin derivatives and analogs.
Insulin derivatives are derivatives of naturally occurring insulins, namely human insulin or animal insulins, which differ from the corresponding, otherwise identical naturally occurring insulin by substitution of at least one naturally occurring amino acid residue and/or addition of at least one amino acid residue and/or organic residue.
In general, insulin derivatives have a slightly modified action compared with human insulin.
Insulin derivatives having an accelerated onset of action are described in EP 0 214 826, EP 0 375 437 and EP 0 678 522. EP 0 124 826 inter alia relates to substitutions of B27 and B28. EP 0 678 522 describes insulin derivatives which have at position B29 various amino acids, preferably proline, but not glutamic acid. EP 0 375 437 includes insulin derivatives with lysine or arginine at B28, which may additionally be modified at B3 and/or A21 , where appropriate.
EP 0 419 504 discloses insulin derivatives which are protected against chemical modification by modification of asparagine at B3 and of at least one other amino acid at positions A5, A15, A18 or A21.
WO 92/00321 describes insulin derivatives in which at least one amino acid at positions B1-B6 has been replaced by lysine or arginine. According to WO 92/00321 , insulins of this kind exhibit a prolonged action.
When producing insulin and insulin derivatives by genetic engineering, an insulin precursor, "proinsulin", comprising B, C and A chains is frequently expressed. Said proinsulin can be converted into insulin or an insulin derivative by enzymatic or chemical removal of the C chain after appropriate and correct folding and formation of the disulfides bridges. Proinsulin is frequently expressed in the form of a fusion protein. The "unwanted" fusion partner likewise needs be removed chemically or enzymatically.
It is obvious to the skilled worker that the choice of recombinant host/vector systems determines the methods for cultivation, propagation and fermentation of the recombinant cells. This is likewise a subject of the invention.
The fusion protein shows surprisingly good solubility in acidic medium, and this leads to distinct advantages regarding the chemical workup of the protein. Firstly, many
unwanted components of the supernatant are precipitated under said conditions and, secondly, peptidases or proteases are inactive. Thus, acidifying the fermentation broth at the end of the operation makes it possible to directly separate unwanted supernatant proteins together with the host cells from the fusion protein and, in a further step, to concentrate said fusion protein. This is likewise a subject of the invention.
At the end of the fermentation, the folding process may not yet be 100% complete. The addition of mercaptan or, for example, cysteine hydrochlohde can complete the process. This is likewise a subject of the invention.
If the two proteins are fused via a linker of amino acids which are specifically recognized by endoproteases which efficiently cleave the fusion protein at no other position, then the protein of interest can be cleaved off directly in active form. In the case of insulin production, the linker between hirudin and proinsulin preferably contains arginine at the carboxy-terminal end. In simultaneous processing it is then possible by conversion with trypsin to cleave off the fusion part and convert proinsulin to mono- or di-Arg-insulin. Said linker must be optimized in relation to insulin processing such that cleaving off the hirudin part is not slower than cleavages in the C peptide sequence or a derivative thereof which links the B and A chains of insulin. This is likewise a subject of the invention. An example of an expression system which can be used is the vector pJF118, described in figure 1 of European patent 0 468 539.
Plasmids which contain DNA sequences encoding proinsulin or proinsulin derivatives are described, for example, in the patents EP-A 0 489 780 and PCT/EP00/08537.
The plasmid pK152 which contains the sequence for hirudin according to EP-A 0 324 712 is used as source of the DNA sequence for hirudin.
The export compatibility of the protein of interest for passing through the inner bacterial membrane is important for secretion. In this context, the choice of signal sequence which can be more or less optimal for different proteins is important. The patent
application PCT/EPOO/08537 describes a system of PCR-based signal sequence screening. This system can also be applied to fusion proteins having hirudin as the N- terminal fusion part, since hirudin activity surprisingly remains intact and thus becomes readily detectable in the supernatant by means of the thrombin inhibition assay.
The invention therefore relates to a DNA (alternative term: expression cassette) encoding a fusion protein of the form
- F- Asm - Rn - Y - , where
F is a DNA sequence coding for an amino acid sequence which allows secretion of a protein Y into a fermentation medium, As is a chemical bond or a DNA sequence coding for an amino acid encodable by the genetic code, m is an integer from 0 - 10,
R is a chemical bond or an arginine codon, n is 0 or 1 , and
Y is a DNA sequence coding for a protein of interest which, correctly folded, is part of the fusion protein in the fermentation medium, choosing in particular a DNA sequence coding for hirudin or a derivative thereof
(F) and proinsulin or a derivative thereof (Y).
The invention further relates to an expression cassette (alternative term: DNA- molecule) of the form
P - S - F - Asm - Rn - Y - T, where
P is a promoter,
S is a DNA sequence coding for a signal sequence allowing optimal yields, T is an untranslated expression-enhancing DNA sequence.
The invention further relates to a plasmid containing an above-described expression cassette and to a host cell containing said plasmid or to a host cell which preferably contains the expression cassette integrated into the host genome, the host cell being selected from a group comprising E.coli, B. subtilis and Streptomyces.
The invention also relates to a process for the fermentative production of a fusion protein as described above, in which process
(a) an DNA molecule as described above is expressed in a host cell as described above and (b) the expressed fusion protein is isolated;
in which, in particular, the supernatant is separated from the host cells to isolate the expressed protein, and the expressed protein is isolated from the supernatant; and in which a process step for concentrating the expressed protein in the supernatant after precipitation is selected from a group comprising microfiltration, hydrophobic interaction chromatography and ion exchange chromatography, and in which a particular embodiment is that isolation of the expressed protein includes a step in which components of the culture medium or the supernatant are precipitated, while the expressed protein remains in solution; and in which in a further preferred embodiment of the invention, after the fermentation, mercaptan or cysteine hydrochlohde are added to the fermentation supernatant at pH 6 - 9, resulting in a free SH group concentration of from 0.05 to 2.5 mM.
A particular embodiment of the invention comprises separating the fermentation supernatant from the host cells, further culturing the host cells in fresh medium and isolating the released fusion protein from the supernatant. In other words, a further embodiment of the invention is a process as described above, in which process after separating the fermentation supernatant from the host cells, the host cells are repeatedly cultured in fresh medium, and the released fusion protein is isolated from each supernatant obtained during cultivation. The invention further relates to a process for the production of insulin or an insulin derivative, in which process
(a) from the expressed protein which is obtained in a process as described above
(b) the protein of interest, in particular insulin or insulin derivative, is released by enzymatic or chemical cleavage and (c) is isolated.
The following examples which are not intended to be restrictive describe the invention in more detail.
Example 1 : Construction of a lepirudin-GNSAR-simian proinsulin fusion protein, appended to the signal sequence of the oprF gene product from Pseudomonas fluorescens
Example 2 of the patent application PCT/EPOO/08537 described an expression vector which allows expression and secretion of Refludan into the medium used for E. coli via the signal sequence of the Pseudomonas fluorescens oprF gene product (De, E. et al.
FEMS Microbiol Lett.127,263 -272, 1995 ). This vector serves to construct a
Refludan-GNSAR-simian proinsulin fusion protein (GNSAR=SEQ ID NO.: 1 ) and is denoted pBpfu_hir.
Further starting materials are pJF118 (EP 0 468 539) and pK152 (PCT/EPOO/08537) plasmid DNAs. The following oligonucleotides are required:
Primer pfufl 5'GGTTCTCTTA TTGCCGCTAC TTCTTTCGGC GTTCTGGCAc ttacgtatac tgactgca 3' (SEQ ID NO.: 2)
Primer insul 1 hindlll 5' - TTTTTAAGCT TCATGTTTGA CAGCTTATCA T -3' (SEQ ID NO.: 3)
Primer Hir insfl
5' ATCCCTGAGG AATACCTTCA GGGAAATTCG GCACGATTTG TG - 3 '(SEQ ID NO.: 4)
Primer Hir_insrev1 5' - CACAAATCGT GCCGAATTTC CCTGAAGGTA TTCCTCAGGG AT -3 '(SEQ ID NO.: 5)
Primer pfufl hybridizes with the DNA region encoding the junction of signal sequence and lepirudin in the expression vector.
The part of primer Hir_insrev1 shown in bold type hybridizes with the DNA region encoding the junction of preproinsuliπ and simian proinsulin sequences in plasmid plNT90d and with sequences of the 3' end of the hirudin sequence in plasmid pK152.
Primer Hirjnsrevl is 100% complementary to primer Hirjnsfl . Primer Insul 1 Hindlll marks the 3' end of the DNA region cloned in plNT90d and encoding the simian proinsulin sequence and additionally carries the hexanucleotide sequence for recognition by the restriction enzyme Hindlll.
Two standard polymerase chain reactions are carried out using the Hirjnsfl / Insul 1 Hindlll primer pair with plasmid plNT90d as template and the pfufl/ Hirjnsrev primer pair with plasmid pBpfu_hir as template. The products of both reactions are combined and an aliquot is converted in a third polymerase chain reaction with primers pfuf1/lnsu11 Hindlll. The result is a DNA product which contains the sequence signal (partially)-lepirudin-GNSAR- simian proinsulin. The DNA fragment is converted using restriction enzymes BamHI and Hindlll, with BamHI cleaving in the lepirudin sequence and Hindlll at the 3' end of the proinsulin-encoding sequence.
In a parallel reaction, vector pBpfu is converted using the two enzymes and the large vector fragment is isolated. The isolated products of both reactions are converted in a T4 ligase reaction. Competent cells of the E. coli strain K12 Mc1061 (Sambrook et al. "Molecular Cloning" (Cold Spring Habor Laboratory Press 1989) are transformed with the ligation mixture and plated on NA plates containing 25μg /ml ampicillin. Plasmid
DNA is isolated from transformants for characterization. At the same time, a plate with the transformants characterized in the plasmid analysis is produced for maintenance purposes. The DNA is characterized by means of restriction analysis and DNA sequence analysis. A plasmid identified as correct was denoted pBpfuHirJns. 5
Example 2: Construction of a Ser-hirudin-GNSAR-simian proinsulin fusion protein appended to the signal sequence of S. typhimurium outer membrane protein (fimD)
10 The construction is carried out according to the plan described in example 1.
Example 10 of patent application PCT/EP 00/08537 describes the construction of a vector for exporting lepirudin via the signal sequence of S. typhimurium outer membrane protein (Rioux.C.R., Fhedrich.M.J. and Kadner,R.J.;J. Bacteriol. 172 (11 ), 15 6217-6222 (1990)) . The resulting plasmid is denoted pBstyfimJiir for laboratory purposes. DNAs of plasmids pK152 and plNT90d serve in each case as templates.
The construction requires 4 primers.
0 The primers insul 1 Hindlll, Hirjnsfl and Hirjnsrevl are described in example 1.
The primer styfimfl ser is newly synthesized and has the following sequence:
5' CGGCGCTGAG TCTCGCCTTA TTTTCTCACC TATCTTTTGC CTCTacgtat 5 actgactgcaCTG 3' (SEQ ID NO.: 6)
The DNA triplet shown in bold type indicates a serine codon. As a result, a hirudin is produced which carries serine instead of leucine at position 1 of the amino acid sequence. 0
Corresponding to example 1 , two standard polymerase chain reactions are carried out using the Hirjnsfl / Insul 1 Hindlll primer pair with plNT90d DNA as template and the
styfimflser / Hirjnsrev primer pair with pK152 DNA as template. The products of both reactions are combined and an aliquot is converted in a third polymerase chain reaction with primers styfimfl ser /Insul 1 Hindlll. The result is a DNA product which contains the sequence signal (partially)-Ser-hirudin-GNSAR- simian proinsulin. The DNA fragment is converted using the restriction enzymes BamHI and Hindlll.
In a parallel reaction, vector pBstyfim_Hir is converted using the two enzymes and the large vector fragment is isolated. The isolated products of both reactions are converted in a T4 -ligase reaction. Competent cells of E. coli strain K12 Mc1061 are transformed with the ligation mixture, and plasmid DNA is isolated from transformants for characterization. At the same time, a plate with the transformants characterized by plasmid analysis is produced for maintenance purposes. The DNA is characterized by means of restriction analysis and DNA sequence analysis. A plasmid identified as correct was denoted pBstyfim_SerHir_lns.
Example 3: Construction of an Ala-hirudin-R-simian proinsulin fusion protein appended to the signal sequence of the E. coli alkaline phosphatase precursor protein
The E. coli alkaline phosphatase precursor has the signal sequence:
MKQSTIALAL LPLLFTPVTK A (SEQ ID NO.: 7)
(Shuttleworth H., Taylor J., Minton N.; Nucleic Acids Res. 14:8689, (1986)).
The peptide sequence is translated into DNA by the GCG program Backtranslate
(Wisconsin Package Version 10.1 , Genetics Computer Group (GCG), Madison, Wise. ) using the E. coli high codon usage criteria.
This results in the sequence:
5'ATGAAACAGTCGACCATCGCGCTGGCGCTGCTGCCGCTGCTGTTCACCCCGGT TACCAAAGCG 3' (SEQ ID NO.: 8)
To clone and append this sequence to a DNA sequence coding for a hirudin which is characterized by having the amino acid alanine at position 1 (EP-A 0 448 093 ), said sequence is extended by the sequence shown in bold type:
5' I I I I I I GAATTCATGAAACAGTCGACCATCGCGCTGGCGCTGCTGCCGCTGCTGTTCAC CCCGGTTACCAAAG -CG GCTacgtat actgactgcaCTG (SEQ ID NO.: 9)
Two oligonucleotide sequences which partially overlap are derived therefrom.
Primer phoafl has the sequence : 5'CTGCTGCCGCTGCTGTTCACCCCGGTTACCAAAGCG GCTACG TATACTGACTGCACTG -3' (SEQ ID NO: 10)
Primer phoaf2 has the sequence:
5' I I I I I I GAATTCATGAAACAGTCGACCATCGCGCTGGCGCTGCTGCCGCTGCTG -3' (SEQ ID NO.: 11)
The construction of the expression vector requires primers insul 1 Hindlll , Hirjnsf2 and Hirjnsrev2 and DNAs of plasmids pK152, plNT90d and pJF118.
Primer Hir_insf2 has the sequence:
5' - ATCCCTGAGGAATACCTTCAGcqaTTTGTGAACCAGCAC C -3'(SEQ ID NO. 12)
Primer Hirjnsrev2 has the sequence: 5' - GGTGCTGGTTCACAAAtcqCTGAAGGTA TTCCTCAGGG AT-3'(SEQ ID NO.13)
Upper case letters in bold type indicate the sequence hybridizing with proinsulin, while upper case letters in plain type describe overlap with the 3' end of the hirudin
sequence. Lower case letters underlined and in bold type represent the codon for the linker arginine.
Corresponding to example 1 , two standard polymerase chain reactions are carried out using the Hirjnsfl / Insul 1 Hindlll primer pair with plNT90d DNA as template and the phoafl / Hirjnsrev primer pair with pK152 DNA as template. The products of both reactions are combined and an aliquot is converted in a third polymerase chain reaction with primers phoa /Insul 1 Hindlll. The result is a DNA product which contains the sequence signal-Ala-hirudin-GNSAR- simian proinsulin. The DNA fragment is converted using restriction enzymes BamHI and Hindlll. In a parallel reaction, vector pjF118 is converted using the two enzymes and the large vector fragment is isolated. The isolated products of both reactions are converted in a T4-ligase reaction. Competent cells of E. coli strain K12 Mc1061 are transformed with the ligation mixture, and plasmid DNA is isolated from transformants for characterization. At the same time, a plate with the transformants characterized by plasmid analysis is produced for maintenance purposes. The DNA is characterized by means of restriction analysis and DNA sequence analysis. A plasmid identified as correct was denoted pNS22.
Example 4: Thrombin inhibition assay
The hirudin concentration is determined according to the method of Gheβbach et al. (Thrombosis Research 37, pp. 347 -350 , 1985 ). For this purpose, specific amounts of a Refludan standard are included in the measurements in order to establish a calibration curve from which the yield in mg/l can be determined directly. The biological activity is also a direct measure for correct folding of the proinsulin component of the fusion protein. Alternatively, it is possible to use a proteolytic S. aureus digestion and subsequent analysis in an RP-HPLC system to determine the correct S-S bridge formation.
Example 5: Expression of the fusion protein
Recombinant cells are cultivated overnight in 2YT medium (per liter: 16 g of tryptone, 10 g of yeast extract, 5 g of NaCI ) containing 100 μg/ml ampicillin. The overnight culture is diluted 1 :50 with fresh medium and the cells are cultivated to a density of approximately 0.8 OD60o-
Expression is then induced by adding IPTG in such a way that a concentration of 0.05- 2 mM is established. The cells induced in this way are incubated for a further 3-26 h.
After three hours, an antithrombin action of hirudin is clearly measurable in the supernatant. Said action can be attributed to secretion of the desired fusion protein, since SDS PAGE analysis, after Coomassie blue staining, reveals only in induced cells a new band which reacts in Western blot analysis with polyclonal anti-insulin antibodies. In fermentation experiments, induction is commenced only after cultivation to significantly higher optical densities. Preference is given here to synthetic media based on minimal medium. Cell productivity can be increased by using the principle of bacterial milking, i.e. by carefully removing the cells, after the optimal induction time, from the supernatant and further incubating them in fresh medium to which the inducer can again be added. Insulin is then prepared in parallel from the harvested supernatant.
Example 6: Purification of the fusion protein
After induction has finished, the cell supernatant is adjusted to pH 2.5 - 3 and cells and supernatant components are removed by centrifugation or filtration. The supernatant of the precipitation is applied to a cation exchange column (S - Hyper DF, Source 30S) and fractionated using a linear gradient from 150 to 450 mM NaCI at pH 3.5 in the presence of 30% 2-propanol. The individual fractions are analyzed by means of RP-HPLC. The proinsulin-hirudin fusion protein is eluted at an NaCI
concentration of about 300 mM. Sufficiently pure fractions are combined, diluted with 0,1 % TFA and applied to an RP column (PLRP -S 7.5 x 50 mm) by pumping. Elution is carried out using a gradient of 25-50% acetonitrile. Two groups of fractions are pooled. After removing the solvent, the material is freeze-dried. The purity of the material is checked by means of SDS polyacrylamide electrophoresis. The purified fusion protein is analyzed by mass spectrometry (ESI). The experimentally determined molecular weight of the fusion protein corresponds to its theoretically expected molecular weight after removal of the signal peptide.
Example 7: Determination of the disulfide bridge linkage
The fusion protein is digested with trypsin and the fragments formed are analyzed by means of RP-HPLC and subsequently by means of mass spectrometry. A fragment which is recognized as de-(B30) insulin, due to its mass of 5706 Da, is successfully identified. This product is subjected to S. aureus V8 protease digestion. RP-HPLC analysis shows the expected peptide pattern.
Trypsin cleavage is carried out as follows:
The freeze-dried fusion protein is dissolved in 50 mMTris-HCI pH 8 (1 mg/ml), and trypsin (1 μg per mg of fusion protein) is added. Trypsin is inactivated at pH 3 at the end of the reaction.
The S. aureus digestion is carried out as follows:
The isolated de-( B30) insulin is dissolved in water at pH 8, S. aureus protease (1/50 of the amount of insulin) is added, and the mixture is incubated at 37°C for 5 hours and then at room temperature overnight.
Example 8: Purification of insulin
In contrast to most other polypeptides found in the supernatant due to either spontaneous lysis of host cells or secretion, the fusion protein is surprisingly not precipitated at pH 2.5-3,5. The culture medium is therefore acidified appropriately and then, after completion of the precipitation, the precipitate and the cells are removed by centrifugation or by microfiltration and concentrated.
Subsequently, the medium is adjusted to pH 6.8 and the fusion protein content is determined in parallel by analytical HPLC measurement. The determination is followed by adding trypsin to the supernatant so that trypsin is at approx. 1 μg per 1-1.5 mg of fusion protein. After incubation at room temperature for approx. 4 hours, purification is carried out by cation exchange chromatography at pH 3.5 in the presence of 2- propanol. Elution is carried out in the buffer by applying a gradient of from 0.15 to 0.45 M.
Di-Arg-insulin is eluted at approx. 0.3 M. After 1 :1 dilution, di-Arg-insulin is precipitated from the insulin-containing fractions at pH 6.8 with the addition of a 10% strength ZnCI2 solution. Insulin is filtered off and then dissolved in 0.05 M Tris-HCI (pH 8.5) resulting in a 2 mg/ml solution: Then the amount of approximately 1 unit of carboxypeptidase B per 100ml solution is added and the reaction is carried out with gentle stirring. The pH is then adjusted to pH 5.5 with citric acid, and insulin is crystallized in the presence of ZnCI2. The crystals are removed, dissolved and, after purification by RP-HPLC, insulin is purified again by crystallization.
Example 9: Processing of the fusion protein directly in the culture medium
At the end of the expression period, the culture medium is adjusted to pH 6.8 and trypsin is then added with stirring so that a final concentration of 4-8 mg per liter is established. After incubation for approx. 4 hours, the fermentation broth treated in this way is adjusted to pH 2.5-3. After 1-6 hours of precipitation, the pH is raised to 3.5, and the di-Arg-insulin formed is purified via cation exchange chromatography in the
presence of 30% 2-propanol. Elution is carried out by means of an NaCI gradient of 0.05-0.5 M salt. The product-containing fractions are diluted 1 :1 with H20 and then ZnCI2 is added, so that a 0.1 % strength ZnCI2 solution is formed. Di-Arg-insulin precipitates at pH 6.8 and by way of example is converted to insulin according to example 8.
Example 10: Further signal sequences for the secretion of fusion proteins
Using the technique described by the patent application PCT/EPOO/08537 further signal sequences leading to the secretion of hirudin - proinsulin fusion protein could be detected :
Signal sequence smompa derived from the ompA gene for major outer membrane protein of Serratia marcescens ( GenEMBL data base locus: SMOMPA, 1364 bp DNA BCT 30-MAR-1995 )
Signal sequence ecoompc derived from E.coli ompC gene coding for major outer membrane protein ( GenEMBL data base locus : SMOMPA, 1364bp,DNA BCT 30- MAR-1995)
Signal sequence af009352 derived from Bacillus subtilis osmoprotectant binding protein precursor (opuCC) ( GenEMBL data base locus: AF009352, 4500bp, DNA BCT 23-JUL-1997)
Signal sequence aeoxyna derived from Aeromonas caviae xynA gene for xylanase I precursor ( GenEMBL data base locus : AEOXYNA, 1139bp, DNA BCT 07-FEB-1999)
Signal sequence stompsl derived from S.typhi gene for outer membrane protein S1 ( GenEMBL data base locus : STOMPS1 ,1938 bp, DNA BCT 24-AUG-1995)
Claims (18)
1. A DNA coding for a fusion protein of the form
-F-Asm-Rn -Y- where
F is a DNA sequence coding for an amino acid sequence which allows secretion of a protein Y into a fermentation medium,
As is a chemical bond or a DNA sequence coding for an amino acid encodable by the genetic code, m is an integer from 0 - 10,
R is a chemical bond or an arginine codon, n is 0 or 1 , and
Y is a DNA sequence coding for a protein of interest which, correctly folded, is part of the fusion protein in the fermentation medium.
2. A DNA according to claim I, wherein the expression cassette is of the form
P - S - F - ASm - Rn - Y - T
where
P is a promoter,
S is a DNA sequence coding for a signal sequence allowing optimal yields,
T is an untranslated expression-enhancing DNA sequence.
3. A DNA according to claim 2, wherein S is the oprF gene from Pseudomonas fluorescens, the DNA encoding the signal sequence of S. typhimurium outer membrane protein (fim D), the DNA sequence encoding the signal sequence of the E. coli alkaline phosphatase precursor protein, the DNA sequence encoding the signal sequence smompa derived from the ompA gene for major outer membrane protein of Serratia marcescens, the DNA sequence encoding the signal sequence ecoompc derived from E.coli ompC gene coding for major outer membrane protein, the DNA sequence encoding the signal sequence af009352 derived from Bacillus subtilis osmoprotectant binding protein precursor (opuCC), the DNA sequence encoding the signal sequence aeoxyna derived from Aeromonas caviae xynA gene for xylanase I precursor, or the DNA sequence encoding the signal sequence stompsl derived from S.typhi gene for outer membrane protein S1.
4. A DNA according to any of claims 2 or 3, wherein the DNA sequence F is lepirudin, Ser-hirudin or Ala-hirudin.
5. A DNA according to any of claims 2 to 4, wherein the protein of interest Y is a proinsulin, an insulin or a derivative thereof.
6. A protein encoded by a DNA according to any of the claims 1 to 5.
7. A plasmid comprising a DNA according to any of claims 1 to 5.
8. A host cell comprising a plasmid according to claim 7.
9. A host cell comprising a DNA according to any of claims 1 to 5.
10. A host cell according to claims 8 or 9, wherein the cell is selected from the group comprising E. coli, B. subtilis and Streptomyces, and the plasmid according to claim 7 and the DNA according to any of claims 1 to 5 is optionally integrated in the genome of the host cell.
11. A process for the fermentative production of a fusion protein in which process
(a) a DNA molecule according to any of claims 1 to 5 is expressed in a host cell according to any of claims 8 to 10; and
(b) the expressed fusion protein is isolated.
12. A process according to claim 11 , wherein the supernatant is separated from the host cell to isolate the expressed protein, and the expressed protein is isolated from the supernatant.
5 13. A process according to any of the claims 11 or 12, wherein a process step for concentrating the expressed protein in the supernatant after precipitation is selected from a group comprising microfiltration, hydrophobic interaction chromatography and ion exchange chromatography.
10 14. A process according to any of claims 1 1 to 13, wherein isolation of the expressed protein includes a step in which components of the culture medium or the supernatant are precipitated, while the expressed protein remains in solution.
15 15. A process according to any of claims 1 1 to 14, wherein after the fermentation, mercaptan or cysteine hydrochlohde are added to the fermentation supernatant at pH 6-9, resulting in a free SH group concentration from 0.05 to 2.5 mM.
16. Process according to any of claims 11 to 15, in which process after separating 0 the fermentation supernatant from the host cells, the host cells are repeatedly cultured in fresh medium, and the released fusion protein is isolated from each supernatant obtained during cultivation.
17. Process according to any of claims 11 to 15 in which mercaptane or cystein 5 hydrochloride is added to the supernatant of the cell culture at pH 6 - 9, so that a concentration of 0,05 to 2,5 mM of free SH-groups is reached.
18. A process for the production of insulin or an insulin derivative, in which process
0 (a) from the expressed protein which is obtained in a process according to any of claims 11 to 17, (b) the protein of interest, in particular insulin or insulin derivative, is released by enzymatic or chemical cleavage and
(c) is isolated.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10108212A DE10108212A1 (en) | 2001-02-20 | 2001-02-20 | Fusion protein for the secretion of valuable protein in bacterial supernatants |
| DE10108212.6 | 2001-02-20 | ||
| PCT/EP2002/001307 WO2002068660A1 (en) | 2001-02-20 | 2002-02-08 | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002231784A1 true AU2002231784A1 (en) | 2003-03-06 |
| AU2002231784B2 AU2002231784B2 (en) | 2006-10-26 |
Family
ID=7674913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002231784A Expired AU2002231784B2 (en) | 2001-02-20 | 2002-02-08 | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1364029B1 (en) |
| JP (1) | JP4243104B2 (en) |
| KR (1) | KR100858009B1 (en) |
| CN (1) | CN100500853C (en) |
| AT (1) | ATE314480T1 (en) |
| AU (1) | AU2002231784B2 (en) |
| BR (1) | BRPI0207394B8 (en) |
| CA (1) | CA2438886C (en) |
| DE (2) | DE10108212A1 (en) |
| DK (1) | DK1364029T3 (en) |
| ES (1) | ES2254658T3 (en) |
| HK (1) | HK1065335A1 (en) |
| IL (1) | IL157414A0 (en) |
| MX (1) | MXPA03007114A (en) |
| NO (1) | NO331271B1 (en) |
| NZ (1) | NZ527643A (en) |
| PE (1) | PE20020876A1 (en) |
| WO (1) | WO2002068660A1 (en) |
| ZA (1) | ZA200305869B (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| EP2336153B1 (en) | 2003-11-21 | 2016-03-30 | Pfenex Inc. | Improved expression systems with SEC-system secretion |
| JP5602336B2 (en) | 2004-01-16 | 2014-10-08 | フェネックス インコーポレイテッド | Expression of mammalian proteins in Pseudomonas fluorescens |
| WO2006014899A2 (en) | 2004-07-26 | 2006-02-09 | Dow Global Technologies Inc. | Process for improved protein expression by strain engineering |
| DE102006031955A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Process for the preparation of dibasic B chain end insulin analogs |
| DE102006031962A1 (en) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidated insulin glargine |
| DE102006050332A1 (en) | 2006-10-25 | 2008-04-30 | Wacker Chemie Ag | DNA construct and method for the fermentative production of fusion proteins |
| PL2468869T3 (en) | 2007-01-31 | 2015-08-31 | Pfenex Inc | Bacterial leader sequences for increased expression |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| AU2008245696B2 (en) | 2007-04-27 | 2013-11-07 | Pelican Technology Holdings, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| EP2229406B1 (en) | 2008-01-09 | 2015-04-22 | Sanofi-Aventis Deutschland GmbH | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003566A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
| DE102008025007A1 (en) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes and for cartilage regeneration |
| EP2229407B1 (en) | 2008-01-09 | 2016-11-16 | Sanofi-Aventis Deutschland GmbH | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (en) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | New insulin analogs useful for treating diabetes |
| DE102008025008A1 (en) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Insulin analogs which comprise A chain and B chain with disulfide bonds for use in treatment of diabetes |
| EP2344524B1 (en) | 2008-10-02 | 2019-12-04 | Unitargeting Research As | Kit for the optimisation of protein synthesis/secretion |
| KR101939557B1 (en) | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | Combination of an insulin and a GLP-1 agonist |
| CN107308442B (en) | 2009-11-13 | 2022-10-18 | 赛诺菲-安万特德国有限公司 | Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine |
| PT3345593T (en) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
| LT2611458T (en) | 2010-08-30 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| MX370264B (en) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients. |
| AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
| KR20160029731A (en) | 2013-03-12 | 2016-03-15 | 더 제너럴 하스피탈 코포레이션 | Modified mullerian inhibiting substance(mis) proteins and uses thereof for the treatment of diseases |
| JP2017504589A (en) | 2013-12-11 | 2017-02-09 | ザ ジェネラル ホスピタル コーポレイション | Use of Muellerian tube inhibitor (MIS) protein for contraception and preservation of ovarian reserve |
| SI3229828T1 (en) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
| TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341414C (en) * | 1984-03-27 | 2002-12-31 | Paul Tolstoshev | Expression vectors of hirudine, transformed cells and process for the preparation of hirudine |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| ATE176500T1 (en) * | 1990-11-08 | 1999-02-15 | Japan Energy Corp | SECRETION VECTOR, TRANSFORMED MICROORGANISMS CONTAINED AND PRODUCTION OF PRODUCTS BY THE ABOVE MICROORGANISM |
| CA2128689A1 (en) * | 1992-09-28 | 1995-04-06 | Harold T. Pehr | Kicker latch for container closures |
| DE10033195A1 (en) * | 2000-07-07 | 2002-03-21 | Aventis Pharma Gmbh | Bifunctional fusion proteins from hirudin and TAP |
-
2001
- 2001-02-20 DE DE10108212A patent/DE10108212A1/en not_active Withdrawn
-
2002
- 2002-02-06 PE PE2002000081A patent/PE20020876A1/en not_active Application Discontinuation
- 2002-02-08 NZ NZ527643A patent/NZ527643A/en not_active IP Right Cessation
- 2002-02-08 AU AU2002231784A patent/AU2002231784B2/en not_active Expired
- 2002-02-08 CA CA2438886A patent/CA2438886C/en not_active Expired - Lifetime
- 2002-02-08 IL IL15741402A patent/IL157414A0/en active IP Right Grant
- 2002-02-08 BR BRPI0207394A patent/BRPI0207394B8/en not_active IP Right Cessation
- 2002-02-08 KR KR1020037010943A patent/KR100858009B1/en active IP Right Grant
- 2002-02-08 CN CNB028068505A patent/CN100500853C/en not_active Expired - Lifetime
- 2002-02-08 JP JP2002568754A patent/JP4243104B2/en not_active Expired - Lifetime
- 2002-02-08 MX MXPA03007114A patent/MXPA03007114A/en active IP Right Grant
- 2002-02-08 EP EP02711847A patent/EP1364029B1/en not_active Expired - Lifetime
- 2002-02-08 WO PCT/EP2002/001307 patent/WO2002068660A1/en active IP Right Grant
- 2002-02-08 AT AT02711847T patent/ATE314480T1/en active
- 2002-02-08 DE DE60208343T patent/DE60208343T2/en not_active Expired - Lifetime
- 2002-02-08 DK DK02711847T patent/DK1364029T3/en active
- 2002-02-08 ES ES02711847T patent/ES2254658T3/en not_active Expired - Lifetime
-
2003
- 2003-07-30 ZA ZA200305869A patent/ZA200305869B/en unknown
- 2003-08-19 NO NO20033673A patent/NO331271B1/en not_active IP Right Cessation
-
2004
- 2004-10-20 HK HK04108196.1A patent/HK1065335A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1364029B1 (en) | FUSION PROTEIN comprising hirudin and proinsulin or insulin | |
| AU2002231784A1 (en) | Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture | |
| AU605291B2 (en) | Process for the purification of recombinant polypeptides | |
| US7105638B1 (en) | Product and process for the production, isolation, and purification of recombinant polypeptide | |
| US7202059B2 (en) | Fusion proteins capable of being secreted into a fermentation medium | |
| AU2002250903B2 (en) | Use of fusion proteins whose N-termial parts is a hirudin derivative for the production of recombinant proteins via secretion by yeasts | |
| EP0346500B1 (en) | Elastase inhibiting polypeptides and process for their preparation by genetic recombination | |
| AU2002250903A1 (en) | Use of fusion proteins whose N-termial parts is a hirudin derivative for the production of recombinant proteins via secretion by yeasts | |
| US6861237B2 (en) | Production of heterologous polypeptides in yeast | |
| EP1364030B1 (en) | Supersecretable peptides, processes for their production, and parallel improvement of the secreted form of one or more other polypeptides | |
| KR100659671B1 (en) | Process for Producing Recombinant Insulin from Novel Fused Protein | |
| EP0225860A2 (en) | A method to export gene products to the growth medium of Gram negative bacteria | |
| US7344856B1 (en) | Method of controlling cleavage by OmpT protease | |
| KR930003913B1 (en) | Method for preparation of polypeptide having thrombin inhibiting activity | |
| Zhu et al. | Synthesis of peptides using a thioredoxin gene fusion expression system: An application to hirudin | |
| EP1339856A1 (en) | Production of heterologous polypeptides in yeast |